|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Allogene Therapeutics, Inc. (ALLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
140,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190 |
190 |
190 |
190 |
| Total Buy Value |
$683 |
$683 |
$683 |
$683 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
18,640 |
28,640 |
82,742 |
| Total Sell Value |
$0 |
$50,317 |
$93,172 |
$700,150 |
| Total People Sold |
0 |
1 |
2 |
5 |
| Total Sell Transactions |
0 |
1 |
2 |
12 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moore Timothy L. |
Chief Technical Officer |
• • – |
2024-04-22 |
4 |
D |
$3.47 |
$60,189 |
D/D |
(17,360) |
265,459 |
|
- |
|
| Chang David D |
President and CEO |
• • – |
2024-03-14 |
4 |
D |
$4.33 |
$231,192 |
D/D |
(53,393) |
4,465,278 |
|
- |
|
| Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
• • – |
2024-01-30 |
4 |
B |
$3.60 |
$683 |
D/D |
190 |
819,590 |
0.01 |
- |
|
| Belldegrun Arie |
|
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
211,973 |
1,866,859 |
|
- |
|
| Roberts Zachary |
EVP of R&D |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
515,253 |
|
- |
|
| Chang David D |
President and CEO |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
317,800 |
4,513,203 |
|
- |
|
| Moore Timothy L. |
Chief Technical Officer |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
96,600 |
282,819 |
|
- |
|
| Douglas Earl Martin |
SVP, General Counsel |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
41,800 |
477,634 |
|
- |
|
| Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
29,400 |
819,400 |
|
- |
|
| Roberts Zachary |
EVP of R&D |
• • – |
2024-01-22 |
4 |
D |
$3.17 |
$78,376 |
D/D |
(24,690) |
375,253 |
|
- |
|
| Messemer Deborah M. |
|
• • – |
2023-12-18 |
4 |
AS |
$2.70 |
$50,317 |
D/D |
(18,640) |
62,456 |
|
- |
|
| Parker Geoffrey M. |
CHIEF FINANCIAL OFFICER |
• • – |
2023-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
790,000 |
790,000 |
|
- |
|
| Douglas Earl Martin |
GENERAL COUNSEL |
• • – |
2023-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
435,834 |
435,834 |
|
- |
|
| Chen Yinlin Jack |
SVP, Finance |
• – – |
2023-08-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
77,480 |
|
- |
|
| Chen Yinlin Jack |
SVP, Finance |
• • – |
2023-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
11,401 |
88,881 |
|
- |
|
| Mayo Stephen |
|
• • – |
2023-08-07 |
4 |
S |
$4.29 |
$42,855 |
D/D |
(10,000) |
25,328 |
|
- |
|
| Messemer Deborah M. |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
74,561 |
81,096 |
|
- |
|
| Humer Franz B |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
74,561 |
266,453 |
|
- |
|
| Witte Owen N. |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
74,561 |
292,832 |
|
- |
|
| Sato Vicki L |
|
• • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
59,649 |
101,100 |
|
- |
|
| Moore Timothy L. |
Chief Technical Officer |
• • – |
2023-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
186,219 |
186,219 |
|
- |
|
| Smith Lillian |
VP, Corporate Counsel |
• – – |
2023-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,845 |
|
- |
|
| Smith Lillian |
VP, Corporate Counsel |
• • – |
2023-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
56,545 |
140,390 |
|
- |
|
| Belldegrun Arie |
|
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282,976 |
1,654,886 |
|
- |
|
| Roberts Zachary |
EVP of R&D |
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
148,035 |
399,943 |
|
- |
|
221 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
